NO20055309D0 - Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav - Google Patents

Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav

Info

Publication number
NO20055309D0
NO20055309D0 NO20055309A NO20055309A NO20055309D0 NO 20055309 D0 NO20055309 D0 NO 20055309D0 NO 20055309 A NO20055309 A NO 20055309A NO 20055309 A NO20055309 A NO 20055309A NO 20055309 D0 NO20055309 D0 NO 20055309D0
Authority
NO
Norway
Prior art keywords
methods
slurp
coagulation
schemes
compositions
Prior art date
Application number
NO20055309A
Other languages
English (en)
Other versions
NO20055309L (no
NO337494B1 (no
Inventor
Fabrice Chimienti
Ronald Hogg
Marcel Huber
Daniel Bertrand
Daniel Hohl
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20055309D0 publication Critical patent/NO20055309D0/no
Publication of NO20055309L publication Critical patent/NO20055309L/no
Publication of NO337494B1 publication Critical patent/NO337494B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
NO20055309A 2003-04-16 2005-11-10 Sammensetninger som omfatter en effektiv mengde Slurp-1 for anvendelse i behandling av nevrologiske forstyrrelser og hudsykdommer NO337494B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46341803P 2003-04-16 2003-04-16
PCT/IB2004/001716 WO2004091646A2 (en) 2003-04-16 2004-04-16 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction

Publications (3)

Publication Number Publication Date
NO20055309D0 true NO20055309D0 (no) 2005-11-10
NO20055309L NO20055309L (no) 2006-01-16
NO337494B1 NO337494B1 (no) 2016-04-25

Family

ID=33300074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055309A NO337494B1 (no) 2003-04-16 2005-11-10 Sammensetninger som omfatter en effektiv mengde Slurp-1 for anvendelse i behandling av nevrologiske forstyrrelser og hudsykdommer

Country Status (11)

Country Link
US (2) US7135454B2 (no)
EP (1) EP1613341B1 (no)
JP (1) JP4891065B2 (no)
AT (1) ATE494903T1 (no)
AU (1) AU2004229237B2 (no)
CA (1) CA2520029C (no)
DE (1) DE602004031003D1 (no)
ES (1) ES2359408T3 (no)
IL (1) IL171384A (no)
NO (1) NO337494B1 (no)
WO (1) WO2004091646A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020996A2 (en) * 2004-08-11 2006-02-23 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US7858590B2 (en) * 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US20080221013A1 (en) * 2006-09-02 2008-09-11 Julie Miwa Neurobiological compositions
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
RU2453602C2 (ru) * 2010-08-19 2012-06-20 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pЕТ22b(+)/SLURP-1, КОДИРУЮЩАЯ БЕЛОК SLURP-1, И ШТАММ БАКТЕРИЙ Escherichia coli BL21(DE3)/pET22b(+)/SLURP-1-ПРОДУЦЕНТ БЕЛКА SLURP-1 ЧЕЛОВЕКА
AU2011305462B2 (en) 2010-09-23 2015-11-26 Abbvie Bahamas Ltd. Monohydrate of an azaadamantane derivative
EP3848055A1 (en) 2011-06-03 2021-07-14 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
EP2740485B1 (en) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 for use in the treatment of ocular diseases
CN114601915B (zh) * 2022-03-25 2023-04-07 四川大学华西医院 Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5298604A (en) * 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes
IT1257184B (it) * 1992-12-22 1996-01-10 Applied Research Systems Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
EA001077B1 (ru) 1996-04-24 2000-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения
WO1998056810A2 (de) * 1997-06-09 1998-12-17 Forssmann Wolf Georg Humanes protein lus-i, seine herstellung und verwendung
ATE224200T1 (de) 1998-07-09 2002-10-15 Applied Research Systems Komponente b als angiogenes mittel zusammen mit humanen wachstumsfaktoren

Also Published As

Publication number Publication date
ATE494903T1 (de) 2011-01-15
EP1613341B1 (en) 2011-01-12
CA2520029A1 (en) 2004-10-28
AU2004229237B2 (en) 2009-06-04
US20070219130A1 (en) 2007-09-20
JP2006523678A (ja) 2006-10-19
CA2520029C (en) 2014-07-15
NO20055309L (no) 2006-01-16
ES2359408T3 (es) 2011-05-23
US7135454B2 (en) 2006-11-14
EP1613341A2 (en) 2006-01-11
JP4891065B2 (ja) 2012-03-07
AU2004229237A1 (en) 2004-10-28
US20050004025A1 (en) 2005-01-06
WO2004091646A2 (en) 2004-10-28
US7691808B2 (en) 2010-04-06
WO2004091646A3 (en) 2004-12-16
NO337494B1 (no) 2016-04-25
IL171384A (en) 2010-12-30
DE602004031003D1 (de) 2011-02-24

Similar Documents

Publication Publication Date Title
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
NO20034056D0 (no) Proliferative sykdommer
DE60239931D1 (de) Kombinationstherapie
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
IS8004A (is) Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
TW200636242A (en) Methods of modulating the activities of α7 nicotinic acetylcholine receptor
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
WO2006135694A3 (en) Uii-modulating compounds and their use
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
MXPA03008039A (es) Polipeptidos de serpina humanos.
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
UA85187C2 (en) 2-aminobenzoyl derivatives
DE60005526D1 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

MM1K Lapsed by not paying the annual fees